WDM(SH:600055)2022-04-22 16:00Financial Performance - The company's operating revenue for 2021 was ¥1,156,174,686.02, representing a 2.14% increase from ¥1,131,904,792.40 in 2020[20] - The net profit attributable to shareholders for 2021 was ¥183,193,054.55, a decrease of 16.98% compared to ¥220,667,405.92 in 2020[20] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥159,634,050.73, down 29.21% from ¥225,501,400.99 in the previous year[20] - The net cash flow from operating activities was ¥89,723,684.83, a significant decline of 82.75% from ¥520,025,424.07 in 2020[20] - The total assets at the end of 2021 were ¥2,875,979,734.33, a slight increase of 0.57% from ¥2,859,758,301.07 at the end of 2020[20] - The net assets attributable to shareholders at the end of 2021 were ¥2,396,012,169.64, reflecting a 4.96% increase from ¥2,282,816,377.57 in 2020[20] - Basic earnings per share for 2021 were ¥0.342, down 16.99% from ¥0.412 in 2020[21] - The weighted average return on net assets for 2021 was 7.81%, a decrease of 2.28 percentage points from 10.09% in 2020[21] Revenue and Sales - In 2021, the company achieved operating revenue of 1.156 billion yuan, a year-on-year increase of 2.14%[33] - The net profit attributable to the parent company was 183 million yuan, a year-on-year decrease of 16.98%[33] - Sales expenses reached 185 million yuan, representing 16.04% of revenue, with a year-on-year increase of 28.28%[33] - Sales of mobile DR decreased by 61.57% year-on-year, totaling 319 units sold[34] - The company sold 64 units of superconducting MRI, a year-on-year increase of 204.76%[37] - The sales volume of superconducting 1.5T MRI products significantly increased year-on-year, ranking fifth in the industry by sales units and second among domestic brands[52] - Sales of DR products totaled 1,463 units, down 18.72% year-on-year, while mobile DR sales decreased by 61.57% to 319 units[71] - MRI sales increased by 119.30% year-on-year, reaching 125 units sold[71] Research and Development - R&D expenses amounted to 111 million yuan, accounting for 9.64% of revenue, with a year-on-year increase of 29.01%[33] - The company plans to increase R&D investment and recruitment to enhance product quality and reduce the gap with leading brands[52] - The company has invested in the development of new products, including a 3.0T superconducting MRI system and a 32-slice CT scanner, contributing to the increase in R&D expenses[86] - The number of R&D personnel increased by 23.19% year-on-year, totaling 170, which constitutes 19.74% of the company's total workforce[89] - The company has approved the establishment of the Wandong Research Institute to enhance R&D capabilities[151] Market Position and Strategy - The company maintained a leading position in the domestic market for conventional DR, with a market share of 20.11%[34] - The domestic DR product market share exceeded 70%, with domestic superconductor MRI and high-end CT market shares increasing to 30% and 20%, respectively[42] - The company aims to lead the market in specialized fields such as orthopedic diagnosis and treatment through its DR product line, which has completed prototype development[86] - The company is shifting its marketing strategy to target higher-tier hospitals, aligning with the development of its product lines to meet diverse clinical needs[117] - The DSA market is projected to experience high growth due to national policies aimed at enhancing the capabilities of county-level hospitals, with significant demand for DSA equipment from traditional Chinese medicine hospitals[114] Future Outlook - For 2022, the company expects to achieve operating revenue of 1.4 billion yuan and a net profit of 140 million yuan, with estimated period expenses of 500 million yuan[122] - The company plans to invest 2.062 billion yuan from its controlling shareholder to complete four key projects, including the R&D and industrialization of MRI, CT, DSA, and DR products over the next three years[119] - The CT product line is set to undergo a three-phase development plan, with the first phase focusing on enhancing basic CT products in 2022, followed by the launch of mid-tier products in 2023, and high-end products in 2024[117] Corporate Governance and Management - The total pre-tax remuneration for the board members and senior management during the reporting period amounted to 8.168 million yuan[133] - The company has appointed new executives, including three Vice Presidents and a Secretary of the Board, as part of the recent board restructuring[146] - The total number of shares held by the supervisory board chairman, Gao Enyi, remained unchanged at 844 shares[133] - The company has maintained its executive positions in various other organizations, indicating a strong network and influence in the industry[142] - The company’s board of directors has undergone a reshuffle, resulting in the departure of several members, including Wu Qun and Chen Jian[146] Compliance and Internal Control - The internal control audit report for 2021 indicated that the company maintained effective internal controls over financial reporting[171] - The company has not reported any significant internal control deficiencies during the reporting period[171] - The company has maintained compliance with accounting standards and has not faced any major accounting errors[194] - The company has no significant litigation or arbitration matters during the reporting period[197] Shareholder and Dividend Information - The company plans to distribute cash dividends of RMB 1.00 per 10 shares, totaling RMB 70,306,105.80, pending shareholder approval[166] - The company has outlined a shareholder dividend return plan for the next three years (2021-2023)[152]